

Dr. 1. Miller

**The Director of the United States
Patent and Trademark Office**

The
United
States
of
America

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, or importing into the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.



Michelle K. Lee

Director of the United States Patent and Trademark Office



US009096655B2

(12) **United States Patent**
Mittra et al.

(10) **Patent No.:** **US 9,096,655 B2**
(45) **Date of Patent:** **Aug. 4, 2015**

(54) **METHOD FOR IN-VIVO BINDING OF CHROMATIN FRAGMENTS**

(75) **Inventors:** **Indraneel Mittra**, New Delhi (IN); **Rekha Mannemcherril Ramesan**, Kerala (IN); **Chandra Prakash Sharma**, Kerala (IN); **Gopichettipalayam Subbaratnam Bhuvaneshwar**, Kerala (IN); **Kavita Anirban Pal**, Nagpur (IN)

(73) **Assignee:** **TATA MEMORIAL CENTRE**, Parel, Mumbai (IN)

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** **13/575,756**

(22) **PCT Filed:** **Jan. 24, 2011**

(86) **PCT No.:** **PCT/IN2011/000052**

§ 371 (c)(1), (2), (4) **Date:** **Jul. 27, 2012**

(87) **PCT Pub. No.:** **WO2011/092715**

PCT Pub. Date: **Aug. 4, 2011**

(65) **Prior Publication Data**

US 2012/0301487 A1 Nov. 29, 2012

(30) **Foreign Application Priority Data**

Jan. 27, 2010 (IN) 212/MUM/2010

(51) **Int. Cl.**
A61K 47/28 (2006.01)
A61K 39/44 (2006.01)
C07K 16/08 (2006.01)
A61K 47/48 (2006.01)
A61K 39/00 (2006.01)

(52) **U.S. Cl.**
CPC **C07K 16/08** (2013.01); **A61K 47/4823** (2013.01); **A61K 2039/505** (2013.01)

(58) **Field of Classification Search**
CPC **C07K 16/303**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,690,905 A	9/1987	Diamond	
5,354,554 A	10/1994	Rhind	
5,795,719 A	8/1998	Richard et al.	
7,307,166 B1	12/2007	Von Borstel et al.	
7,541,028 B2 *	6/2009	Sung et al.	424/130.1
7,541,031 B2	6/2009	Salfeld et al.	
2007/0092509 A1	4/2007	Mittra et al.	
2008/0131954 A1 *	6/2008	Stone	435/270
2010/0179303 A1 *	7/2010	Natarajan et al.	530/300

OTHER PUBLICATIONS

Drotleff et al., *Eur. J. Pharm. and Biopharm.* 2004, 58:385-407.*

Apoptosis and Autoimmunity from Mechanisms to Treatment, Edited by J.R. Kalden and M. Herrmann. Co. Wiley-Vch, Weinheim (2003), only contents and titles.

Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. *Blood*, 96:2951-64 (2000).

Barada FA Jr, Suratt PM, Davis JS 4th. et. al. Free plasma DNA in patients with pulmonary embolism. *Southern Medical Journal*. Mar. 1980;73(3):345-6, 350.

Bennett M.R. Apoptosis in the cardiovascular system. *Heart* 87, 480-487 (2002).

Benoit M, Fenollar F, Raoult D. et al. Increased levels of circulating IL-16 and apoptosis markers are related to the activity of Whipple's disease. *PLoS ONE*. Jun. 6, 2007;2(6):e494.

Butt AN, Shalchi Z, Hamaoui K. et al. Circulating nucleic acids and diabetic complications. *Ann NY Acad Sci*. Sep. 2006;1075:258-70.

Chang CP, Chia RH, Wu TL. et al. Elevated cell-free serum DNA detected in patients with myocardial infarction. *Clinica Chimica Acta*. Jan. 2003;327(1-2):95-101.

Dellinger EP, Anaya D. A Infectious and immunologic consequences of blood transfusion. *Critical Care* 8, S18-S23 (2004).

D'Intini V et al. Longitudinal study of apoptosis in chronic uremic patients. *Seminars in Dialysis*, 16,467-73 (2003).

Fadeel, B., Orrenius, S., Zhivotovsky, B. Apoptosis in human disease: a new skin for the old ceremony. *Biochem. Biophys. Res. Com.* 266, 699-717 (1999).

Fliedner T.M., Graessle D, Paulsen C. & Reimers K. Structure and functions of bone marrow hemopoiesis: Mechanisms of response to ionizing radiation exposure. *Cancer Biotherapy & Radiopharmaceuticals* 17, 405-425 (2002).

Galeazzi M, Morozzi G, Piccini M. et al. Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. *Autoimmunity Reviews* Jan. 2003;2(1):50-5.

Geiger S, Holdenrieder S, Stieber P. et al. Nucleosomes in serum of patients with early cerebral stroke. *Cerebrovascular Diseases* 2006;21 (1-2):32-7.

Holdenrieder S, Eichhorn P, Beuers U. et al. Nucleosomal DNA fragments in autoimmune diseases. *Ann NY Acad Sci*. Sep. 2006;1075:318-27.

Holdenrieder S, Stieber P, Bodenmuller H. et al. Nucleosomes in serum of patients with benign and malignant diseases. *International Journal of Cancer*. Mar. 20, 2001;95(2):114-20.

(Continued)

Primary Examiner — Gyan Chandra
(74) *Attorney, Agent, or Firm* — Pillsbury Winthrop Shaw Pittman LLP

(57) **ABSTRACT**

A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginate, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.

13 Claims, 11 Drawing Sheets

Full Text

US 9,096,655 B2

Print this page

**METHOD FOR IN-VIVO BINDING OF CHROMATIN
FRAGMENTS**

Indraneel Mittra, New Delhi (IN); Rekha Mannemcherril Ramesan, Kerala (IN); Chandra Prakash Sharma, Kerala (IN); Gopichettipalayam Subbaratnam Bhuvaneshwar, Kerala (IN); and Kavita Anirban Pal, Nagpur (IN)

Assigned to TATA MEMORIAL CENTRE, Parel, Mumbai (IN)

Appl. No. 13/575,756

Filed by Indraneel Mittra, New Delhi (IN); Rekha Mannemcherril Ramesan, Kerala (IN); Chandra Prakash Sharma, Kerala (IN); Gopichettipalayam Subbaratnam Bhuvaneshwar, Kerala (IN); and Kavita Anirban Pal, Nagpur (IN)

PCT Filed Jan. 24, 2011, PCT No. PCT/IN2011/000052

§ 371(c)(1), (2), (4) Date Jul. 27, 2012,

PCT Pub. No. WO2011/092715, PCT Pub. Date Aug. 4, 2011.

Claims priority of application No. 212/MUM/2010 (IN), filed on Jan. 27, 2010.

Prior Publication US 2012/0301487 A1, Nov. 29, 2012

Int. Cl. *A61K 47/28* (2006.01); *A61K 39/44* (2006.01); *C07K 16/08* (2006.01); *A61K 47/48* (2006.01); *A61K 39/00* (2006.01)

CPC *C07K 16/08* (2013.01) [*A61K 47/4823* (2013.01); *A61K 2039/505* (2013.01)]

13 Claims

1. A method for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium of a mammal in need thereof, comprising introducing into the medium a nanoparticle comprising (a) a polymer having a selective affinity to liver of said mammal, and (b) an antibody that binds CCFs, wherein the antibody is covalently bound to the polymer.

Achievements

✓ Method for ex-vivo separation of apoptotic chromatin fragments from blood or plasma for preventive treatment of diverse human diseases.

Inventors : Mittra I, Samant UC, Modi GK, Mishra PK, Bhuvaneshwar

Application No : 14/100, 950

Publication No. US 2014/0099293 A1

✓ Markers for transformed epithelium and potential targets for therapy of cancer of the gingivo buccal cc

European Patent Specification No. EP 2 115 473 B1

Date of publication : 04/06/2014

(ii) Auto antibodies for protein antigens as markers for cancer of gingivo-buccal complex.

United States Patent No. US8 492 100 B2

Date of publication : 23/07/2013

From: Sanjay Gupta/ACTREC
To: Academic Office/ACTREC@ACTREC
Cc: Mushtaq Shaikh/ACTREC@ACTREC

Details are as follows:

Monoclonal antibody targeting Lipocalin 2 for therapeutic usage in cancer overexpressing LCN2: KSA REF : PS1295IN00. || K&S Ref: IP46404

Dr. Sanjay Gupta, Ph.D.
PI & Scientific Officer 'G'
KS#352, CRI-ACTREC, TMC, Navi Mumbai
[+91 \(22\) 27405086](tel:+912227405086); [8652098209](tel:+91228652098209)
Sent from HCL Verses

Welcome KARUNA GOLERIA Sign out

Controller General of Patents, Designs & Trade
Marks
S.M.Road, Antop Hill, Mumbai-400037
Tel No. (091)(022) 241377010, 24141028 Fax No. 022
24130387
E-mail: mumbai-patent@nic.in
Web Site: www.ipindia.gov.in



सत्यमेव जयते

G.A.R.6
[See Rule 22(1)]
RECEIPTINTELLECTUAL
PROPERTY INDIA
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS

Docket No 9943

Date/Time 2017/03/16 12:55:16

KARUNA GOLERIA De Penning & De Penning Alaknanda, 16
Nepent Sen Road, Mumbai 400 036, India Email:
patent@depenning.com

Sr. No.	Ref. No./Application No.	App. Number	Amount Paid	C.B.R. No.	Fee Payment	Remarks
1	E-2/S43/2017/MUM	201621009168	24000	6402	Full	

TransactionID	Payment Mode	Challan Identification Number	Amount Paid	Head of A/C No
N-0000252109	Online Bank Transfer	02806341603201750116	24000.00	14750010200000001

Total Amount : ₹ 24000

Amount in Words: Rupees Twenty Four Thousand Only

Received from KARUNA GOLERIA the sum of ₹ 24000 on account of Payment of fee for above mentioned Application/Forms.

* This is a computer generated receipt, hence no signature required.

Print

[Home](#) [About Us](#) [Contact Us](#)

Welcome KARUNA GOLERIA [Sign out](#)

PATENT OFFICE
INTELLECTUAL PROPERTY BUILDING
S.M.Road, Antop Hill, Mumbai-400037
Tel No. (0911022) 241377010, 24141026 Fax No.
022 24130387
E-mail: mumbai-patent@nic.in
Web Site: www.ipindia.gov.in



सत्यमेव जयते

G.A.R.6
[See Rule 22(1)]
RECEIPT



INTELLECTUAL
PROPERTY INDIA
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS

Docket No 22901

Date/Time 28/10/2015 16:26:29

To
KARUNA GOLERIA

UserId: Dep-Mum

De Penning & De Penning Alaknanda,
16 Nepean Sea Road, Mumbai 400 036,
India

CBR Detail:

Sr. No.	Ref. No./Application No.	App. Number	Amount Paid	C.B.R. No.	Form Name	Remarks
1	4082/MUM/2015		8000	16722	FORM 1	PHOTO-DISINTEGRABLE, NEAR-INFRA RED RESPONSIVE GOLD COATED POLY-(LACTIC-CO-GLYCOLIC ACID) NANOSTRUCT

TransactionID	Payment Mode	Challan Identification Number	Amount Paid	Head of A/C No
N-0000138026	Online Bank Transfer	02806342810201550261	8000.00	1475001020000001

Total Amount : ₹ 8000

Amount in Words: Rupees Eight Thousand Only

Received from KARUNA GOLERIA the sum of ₹ 8000 on account of Payment of fee for above mentioned Application/Forms.

* This is a computer generated receipt, hence no signature required.

[Print](#)
[Home](#) [About Us](#) [Contact Us](#)

3/15/2019

PATENT eFiling

Welcome Rahul Bagga [Sign out](#)

Controller General of Patents, Designs & Trade
Marks



सत्यमेव जयते
G.A.R.6
[See Rule 22(1)]
RECEIPT



Docket No 14639

Date/Time 2019/03/15 17:38:00

To
Rahul Bagga

UserId: rahulbagga

Adastra IP 2054, Sector 8

CBR Detail:

Sr. No.	Ret. No./Application No.	App. Number	Amount Paid	C.B.R. No.	Form Name	Remarks
1	201921010208	TEMP/E-1/10868/2019-MUM	32800	6231	FORM I	A METHOD FOR DETECTION OF PROTEIN ACTIVATION USING PHOSPHO-BRET IMAGING SENSOR AND METHODS THEREOF

TransactionID	Payment Mode	Challan Identification Number	Amount Paid	Head of A/C No
N-0000482921	Online Bank Transfer	1503190005393	32800.00	1475001020000001

Total Amount : ₹ 32800

Amount in Words: Rupees Thirty Two Thousand Eight Hundred Only

Received from Rahul Bagga the sum of ₹ 32800 on account of Payment of fee for above mentioned Application/Forms.

* This is a computer generated receipt, hence no signature required.

[Print](#)

[Home](#)

[About Us](#)

[Contact Us](#)



US010054602B2

(12) **United States Patent**
Jose et al.

(10) **Patent No.:** **US 10,054,602 B2**
(45) **Date of Patent:** **Aug. 21, 2018**

(54) **CONJUGATE OF ESTRADIOL AND APPLICATIONS THEREOF**

(71) Applicant: **CHRIST UNIVERSITY**, Bengaluru, Karnataka (IN)

(72) Inventors: **Iven Jose**, Bangalore (IN); **Shubhada V. Chiplunkar**, Navi Mumbai (IN); **Vinay Jha Pillai**, Bengaluru (IN); **Rahul Verma**, Gurgaon (IN)

(73) Assignee: **CHRIST UNIVERSITY**, Bengaluru (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 13 days.

(21) Appl. No.: **15/682,047**

(22) Filed: **Aug. 21, 2017**

(65) **Prior Publication Data**
US 2018/0052180 A1 Feb. 22, 2018

(30) **Foreign Application Priority Data**
Aug. 19, 2016 (IN) 201641013646

(51) **Int. Cl.**
A01N 37/00 (2006.01)
A61K 31/21 (2006.01)
G01N 33/74 (2006.01)
C09B 23/08 (2006.01)
C07J 43/00 (2006.01)
C07H 1/00 (2006.01)
C09K 11/06 (2006.01)
C07H 5/06 (2006.01)

(52) **U.S. Cl.**
CPC **G01N 33/743** (2013.01); **C07H 1/00** (2013.01); **C07H 5/06** (2013.01); **C07J 43/003** (2013.01); **C09B 23/086** (2013.01); **C09K 11/06** (2013.01); **C09K 2211/1018** (2013.01); **G01N 2333/723** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS
5,588,032 A 12/1996 Johnson et al.
5,677,125 A 10/1997 Holt et al.
6,543,933 B2 4/2003 Stergiopoulos et al.
2007/0292352 A1 12/2007 Marnett et al.

OTHER PUBLICATIONS
Jose et al, J Fluoresc (2011) 21:1171-1177 (Year: 2011).
Edrich, J. "Centimeter- and Millimeter-Wave Thermography—A Survey on Tumor Detection". Journal of Microwave Power, vol. 14:2, pp. 95-104, DOI:10.1080/16070658.1979.11689135, 1979.

* cited by examiner

Primary Examiner — Jean P Cornet
(74) *Attorney, Agent, or Firm* — Oliff PLC

(57) **ABSTRACT**
The present invention relates to conjugate of 17-β estradiol with an analog of indocyanine green dye for the detection of cancers. The invention also provides a method of preparation of the conjugate and method of detection of cancer cells.

6 Claims, 7 Drawing Sheets